Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

tions. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, which has completed initial Phase 1 clinical studies that provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.



Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181


Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve ri
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... Oct. 17, 2014  UBM Medica US announces that ... endocrinologists and other clinicians who treat patients with ... effective use of insulin .  ... insulin replacement therapy – daily injections of one ... decline in the function of pancreatic beta cells. Insulin ...
(Date:10/17/2014)... Oct. 17, 2014  China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... Company has received approval from the China Food ... of human prothrombin complex concentrate ("PCC") at its ... new coagulation factor production facility for Good Manufacturing ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... DIEGO, Nov. 11, 2010 Althea Technologies, Inc., a ... biopharmaceutical and parenteral products, announced today that Rick ...  Mr. Hancock brings twenty-seven years of industry experience and ... company into the future.  Mr. Hancock will lead the ...
... a meeting convened by the U.S. Food and Drug ... took the next step in advancing efforts toward the ... to ensure the safe and effective testing of artificial ... today,s meeting there was a strong consensus among leading ...
Cached Medicine Technology:Althea Technologies Announces Appointment of Rick Hancock as President 2JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 2JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 3JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing 4
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/19/2014)... 2014 Hastings and Hastings, a Phoenix ... service throughout the greater Phoenix area and across Arizona ... regard to catastrophic automobile accidents. Statistics have indicated a ... throughout Arizona. As such, Hastings and Hastings has seen ... for those who have been injured through no fault ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... brain injury rehabilitation clinics and hospitals in the United States as ... currently living with the condition. Researchers believe that the quality and ... victim,s overall outcome. , ... Denver, CO (PRWEB) August ...
... (NASDAQ: QLTI;,TSX: QLT) announced today that QLT USA, ... license agreement with Reckitt Benckiser,Pharmaceuticals Inc. for its ... being retained by QLT USA and its,prior licensees. ... related asset,purchase agreement, QLT USA received an aggregate ...
... Aug. 25 Susan G. Komen for the ... and its sister organization,the Susan G. Komen for ... spread their message about breast self awareness and ... for the uninsured and,underinsured., (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ...
... 25 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... medical devices in China, today released select historical,financial ... As announced in May, 2008, Mindray changed ... Chinese Renminbi effective April 1, 2008.,Accordingly, Mindray has ...
... CHESTER, Ohio, Aug. 25 AtriCure, Inc.,(Nasdaq: ATRC ... cardiac surgical,ablation systems, today announced that it will present ... Thomas Weisel Partners Healthcare Conference at the Four Seasons,Hotel ... Drachman,President and Chief Executive Officer, is scheduled to present ...
... study suggests cautions fail to alert docs to effectiveness ... -- Safety warnings slowed the use of antipsychotic drugs ... the drugs in the elderly increased, a finding which ... patients, Canadian researchers say. , Between late 2002 ...
Cached Medicine News:Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 2Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 3Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 4Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 2Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 3Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Mindray Releases Historical Financial Results Converted into US Dollar Terms 2Health News:AtriCure to Participate at the Thomas Weisel Partners Healthcare Conference and the UBS Global Life Sciences Conference in September 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2
... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
Medicine Products: